51012-64-7

Basic information

• Product Name: 2-bromo-3-methylacetophenone
• Synonyms: 2-bromo-3-methylacetophenone;2-bromo-1-(3-methylphenyl)ethanone;2-broMo-1-(3-Methylphenyl)ethan-1-one;Ethanone, 2-broMo-1-(3-Methylphenyl)-;2-Bromo-1-(m-tolyl)
• CAS NO: 51012-64-7
• Molecular Formula: C₉H₉BrO
• Molecular Weight: 213.08
• Product Categories: Adehydes, Acetals & Ketones;Bromine Compounds
• Mol File: 51012-64-7.mol
• Article Data: 61

Chemical Properties

• Boiling Point: 263.927 °C at 760 mmHg
• Flash Point: 74.59 °C
• Appearance: /
• Density: 1.416 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-bromo-3-methylacetophenone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-3-methylacetophenone(51012-64-7)
• EPA Substance Registry System: 2-bromo-3-methylacetophenone(51012-64-7)

Safety Data

• Hazardous Substances Data: 51012-64-7(Hazardous Substances Data)

Usage

General Description

2-Bromo-3-methylacetophenone, also known as 1-(2-bromo-3-methylphenyl)ethanone or 3-Methyl-2-bromoacetophenone, is a chemical compound and belongs to the class of organic compounds known as benzoyl derivatives. It appears as a beige crystalline powder and has a molecular weight of 231.10 g/mol. It has applications in various chemical reactions due to its structural properties and bromine group. This substance can be harmful if handled improperly, necessitating careful use according to safety standards. In the CAS registry, it is identified with the number 51707-55-2.

Upstream product

• 585-74-0 3-Methylacetophenone 
• 875815-03-5 α,α-dibromo-3'-methylacetophenone 
• 100-80-1 3-methylstyrene 
• 766-82-5 1-ethynyl-3-methyl-benzene 
• 33675-43-3 1-(bromo-ethynyl)-3-methyl-benzene 

Downstream Products

• 1384067-22-4 4-(3-methylphenyl)oxazole-2-(3H)-one 
• 618-47-3 m-toluamide 

Relevant articles and documents

High Chemo-/Stereoselectivity for Synthesis of Polysubstituted Monofluorinated Pyrimidyl Enol Ether Derivatives

A novel intramolecular Smiles rearrangement of α-fluoro-β-keto-pyrimidylsulfones (usually used as a carbon nucleophile) was developed, providing a versatile avenue for synthesis of tri/tetra-substituted monofluorinated pyrimidyl enol ethers. Among these, diverse (Z)-monofluorovinylsulfones and sulfinates were efficiently assembled by adding extra electrophile and fine-tuning reaction conditions. The process is triggered by a keto-enol tautomerism from enol oxyanion to pyrimidine 2-carbon, completely different from the classical carbon nucleophilic addition reaction approach.

Structure-activity relationship studies in substituted sulfamoyl benzamidothiazoles that prolong NF-κB activation

In the face of emerging infectious diseases, there remains an unmet need for vaccine development where adjuvants that enhance immune responses to pathogenic antigens are highly desired. Using high-throughput screens with a cell-based nuclear factor κB (NF-κB) reporter assay, we identified a sulfamoyl benzamidothiazole bearing compound 1 that demonstrated a sustained activation of NF-κB after a primary stimulus with a Toll-like receptor (TLR)-4 agonist, lipopolysaccharide (LPS). Here, we explore systematic structure–activity relationship (SAR) studies on compound 1 that indicated the sites on the scaffold that tolerated modification and yielded more potent compounds compared to 1. The selected analogs enhanced release of immunostimulatory cytokines in the human monocytic cell line THP-1 cells and murine primary dendritic cells. In murine vaccination studies, select compounds were used as co-adjuvants in combination with the Food and Drug Administration approved TLR-4 agonistic adjuvant, monophosphoryl lipid A (MPLA) that showed significant enhancement in antigen-specific antibody titers compared to MPLA alone. Additionally, our SAR studies led to identification of a photoaffinity probe which will aid the target identification and mechanism of action studies in the future.

MAT2A INHIBITORS

Disclosed herein are compounds of Formula (I), that inhibit Methionine Adenosyltransferase 2A (MAT2A) activity. In particular, the invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the